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learn from that? When science meets 
Hollywood, science loses. 
That’s interesting. Care to elaborate? 
Part of the problem in trying to make 
a movie about real animals is that 
they aren’t actors. You can write a 
script — and there was one — but the 
chimps didn’t always follow it! So, like 
a good field worker, one had to adapt 
as the film footage came in and the 
story line changed. In this day and age 
of global warming, disease pandemics, 
and the like, it’s essential for biologists 
to reach out to the general public and 
communicate what we are learning. 
What better way to do this than via the 
silver screen? So when the producers 
approached us saying that they wanted 
to make a film about chimpanzees 
that would adhere to the science and 
what we know about them, it was a 
no-brainer to sign on. In retrospect, 
I was a bit naïve to believe this. In 
biology, we learn that there are always 
trade-offs in life. There were cases 
where telling a good story that will sell 
in theaters clashed with our scientific 
understanding of chimpanzees. In these 
situations, artistic license was favored. 
At the end of the day, I understand and 
can live with the decisions that were 
made, as science doesn’t always make 
for great entertainment. 
What is the biggest challenge in your 
field? As I look back on my career, I 
realize how lucky I have been. Back 
in the late 1970s when I began my 
research on apes, the field was wide 
open. Scant work had been conducted, 
funds to conduct field work were 
flowing, and populations of apes were 
seemingly everywhere to investigate. 
All of this has changed. Several long-
term field studies of apes have been 
carried out and continue to this day. 
We live in a molecular and biomedical 
age, where an increasingly large part 
of the funding pot goes to things other 
than studies of animal behavior and 
field research. Primates today are 
endangered everywhere. Habitat loss, 
hunting, and recurrent outbreaks of 
infectious disease have decimated large 
populations of primates across the 
globe. Sadly, the biggest challenge is to 
ensure that there will be something to 
study in the future. 
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Quick guideGWAS
Jonathan Flint
G-what? GWAS stands for ‘genome 
wide association study’, the favoured 
method for finding genetic variants 
that increase disease risk. In a GWAS, 
allele frequencies of common genetic 
variants are compared between cases 
(those affected by disease) and controls. 
Common variants are those with a minor 
allele frequency greater than about 
5% (the frequency varies in different 
populations). GWASs are also used to 
find genetic variants that contribute to 
variation in quantitative traits that are 
not diseases, such as height or weight. 
For example, a GWAS of obesity looks 
for any variant whose genotypes are 
associated with different mean weights.
How do I carry out a GWAS? Use 
the following simple four-step recipe: 
first, collect phenotypic information 
from thousands of individuals; 
second, extract DNA and genotype 
at least 500,000 single nucleotide 
polymorphisms (SNPs); third, call 
genotypes and detect association using 
one of a variety of (relatively) user-
friendly software packages; fourth, sift 
through the results and identify at least 
one association signal with a P-value 
less than P < 10−8 (Figure 1). Success is 
guaranteed if you work on a disease no 
one has published on before, or if you 
can find additional loci in an important 
disease, such as type 2 diabetes, 
obesity or Crohn’s disease. For the 
latter, carry out your analysis in a novel 
ethnic group (East Asia is currently a 
favourite), or simply double the sample 
size of the last GWAS to increase 
power and thereby identify novel loci. 
Please note though that acronymed 
consortia — not people — write GWAS 
papers. GWAS authorship is turning 
into a field of study in its own right. One 
report counted 21,007 authorships for 
604 GWAS. This is because the sample 
size needed for GWAS is so huge now, 
up to a quarter of a million people. 
Why do I need such a large sample 
size? The reason for the large sample 
is that each genetic locus makes 
such a small contribution to disease 
susceptibility. The effect size is usually 
expressed as an odds ratio — if an odds ratio is two, the increase in risk is 
twofold. Typical GWAS odds ratios are 
about 1.1–1.2. For quantitative traits, 
such as height or weight, the size of 
the effect is usually expressed as a 
percentage of the phenotypic variance 
attributable to the locus. For example, 
if half the variability in height in a 
population is due to alleles at one locus, 
then the locus’ effect size would be 50% 
Typical values are about 0.05%. While 
the sample size required to detect loci 
varies from phenotype to phenotype, it 
is always in the thousands. For Crohn’s 
disease, 2,000 cases were sufficient 
to identify nine loci. For hypertension, 
29,000 individuals were needed to 
detect ten loci.
And why such a low P-value? If you 
are used to working with P < 0.05 to 
get your paper published, P < 10−8 
does seem a little over the top. It’s the 
consequence of testing hundreds of 
thousands of alternative hypotheses 
(hundreds of thousands of markers) 
and this is one reason why you’ll need 
a big sample. Actually, it’s not as bad 
as it sounds, requiring only about 
an eightfold increase in sample size 
compared to what you need for the 
0.05 level. 
Why does GWAS work? The idea 
behind GWAS is that interrogating 
variation at a few hundred thousand 
positions is sufficient to capture the 
bulk of genetic variation. A remarkably 
small amount of sequence (relative to 
our genome’s size of three gigabases) is 
sufficient, because our genomes have 
a relatively simple haplotypic structure, 
such that variants in close proximity are 
highly correlated, forming haplotype 
blocks. And if you are wondering why 
we have this particular haplotype 
structure, then the answer is because 
of human history: it is due to the exit of 
our ancestors from Africa about 100,000 
years ago imposing a population 
bottleneck, and the subsequent 
enormous population expansion. 
When doesn’t GWAS work? Not all 
human populations have the same 
haplotype structure and in some cases 
this can frustrate GWAS success. For 
example, in Africa, haplotype blocks 
are on average smaller, so many more 
markers are needed to capture the 
majority of the population’s common 
genetic variation. Standard GWAS 
approaches don’t work so well there. 
A corollary of the recent human 
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Figure 1. Visualising a GWAS with a Manhattan plot.
The horizontal axis shows the position of every locus that the microarray interrogates. The numbers 
denote chromosomes. The vertical axis is the negative logarithm (base 10) of the P-value (logP) 
of the association between phenotype and genotype. This plot is based on simulated data, but 
the experimenters would be pleased, as there are a number of peaks that exceed a genome-wide 
significance threshold (red line).
Children with autism 
do not overimitate
L. Marsh, A. Pearson, D. Ropar,  
and A. Hamilton
Copying the behaviour of others is 
important for forming social bonds 
with other people and for learning 
about the world [1]. After seeing 
an actor demonstrate actions on a 
novel object, typically developing 
(TD) children faithfully copy both 
necessary and visibly unnecessary 
actions [2]. This ‘overimitation’ is 
commonly described in terms of 
learning about the object, but may 
also reflect a social process such as 
the child’s motivation to affiliate with 
the demonstrator [3] or to conform to 
perceived norms [4]. Previous studies 
of overimitation do not separate 
object learning and social imitation 
because they use novel objects. Even 
though researchers consider these 
objects to be causally transparent in 
their mechanism, young children’s 
causal reasoning about novel objects 
is unclear [4]. The present study 
measures the social component 
of overimitation by using familiar 
objects, which preclude the learning 
component of the task. Here we 
report a significant reduction in 
overimitation in children with autism 
spectrum conditions (ASC). This 
is coherent with reports that these 
children have profound difficulties 
with social engagement [5] and do 
not spontaneously imitate action 
style [6] (see also [7]).
We tested 31 children with ASC, 
30 TD children matched for verbal 
mental age and 30 TD children 
matched for chronological age 
on an overimitation task using 
familiar objects. All children were 
assessed for verbal mental age, 
overimitation and understanding of 
action rationality (see Supplemental 
Information). On each of five trials, 
the child was asked to watch 
carefully as a demonstrator showed 
how to retrieve a toy from a box 
or build a simple object. Critically, 
each demonstration included 
two necessary actions (such as 
unclipping and removing the box lid) 
and one unnecessary action (such as 
Correspondencespopulation expansion is that most 
alleles are rare, and are not interrogated 
by standard commercially available 
microarrays. The full extent of what 
is missed became apparent from 
recent population scale re-sequencing 
projects: only 13% of variants with a 
frequency of less than 0.5% had been 
described previously. If rare variants 
make a substantial contribution to your 
disease of interest, beware! GWAS 
won’t find them. You may also have 
read that GWAS doesn’t work because 
GWAS loci cannot account for much of 
the known or estimated heritability of a 
trait (‘missing heritability’). For instance, 
despite finding 180 loci that influence 
height, these loci account for just 10% 
of the variation. But, this does not take 
account of all those SNPs that don’t 
make the significance threshold. They 
can’t simply be ignored, but what to 
do with them? Peter Visscher has an 
answer, using an approach routine in 
plant and animal genetics. Examining 
the effect of all SNPs, regardless of 
statistical significance, almost half of 
height’s phenotypic variance can be 
explained by common SNPs. So is there 
a ‘missing heritability’ problem? Well, 
we still can’t explain all the variance. 
What have we learnt from GWAS? 
Two common complaints are that 
GWAS gives us genetic loci not genes 
(true!) and that lists of genetic loci 
don’t tell us anything about mechanism 
(true too!). One of the insights of the 
ENCODE project is that GWAS hits lie 
preferentially in regulatory regions of 
the genome (enhancers, promoters and 
other less well categorized elements). 
Tying variation at an enhancer to a particular gene product is admittedly 
hard, but the nearest neighbouring 
gene hypothesis works well (ENCODE 
again helps here, revealing that action 
on the megabase scale is rare, most 
elements operate over a few tens of 
kilobases). Next generation GWAS are 
now including tests of function, testing 
gene expression patterns of nearest-
neighbour genes in relevant tissues, 
and (impressively) in a GWAS for human 
red blood cell phenotypes, haemocyte-
specific RNA interference (RNAi) 
silencing in Drosophila melanogaster.
Does this mean GWAS can deliver 
the holy grail of mechanism? Take 
note, journal editors, genetics is a 
hypothesis-free enterprise! How else 
could mathematicians, statisticians and 
bioinformaticians partake?
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